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The aim of this study was to investigate recent trends in incidence, mortality and survival in patients diagnosed with malignant
melanoma (MM) in relation to stage (Breslow thickness). Cases of primary invasive and in situ MM diagnosed between 1st January
1993 and 31st December 2003 in the former Yorkshire Health Authority were identified from cancer registry data. Over the study
period, the incidence of invasive MM increased from 5.4 to 9.7 per 100000 in male subjects and from 7.5 to 13.1 per 100000 in
female subjects. Most of this increase was seen in thin tumours (o1.5mm). Thin tumours were more likely to be diagnosed in the
younger age groups and be classified as superficial spreading melanoma. In situ melanoma rates increased only slightly. Over the same
time period, mortality rates have been relatively constant in both male and female subjects. Five-year relative survival varied from
91.8% (95% CI 90.4–93.1) for patients with thin tumours to 41.5% (95% CI 36.7–46.3) for those with thick tumours. In multivariable
analyses, Breslow thickness was the most important prognostic factor. Age, sex and level of deprivation were also identified as
independent prognostic factors. The trends in incidence suggest that the increase is real, rather than an artefact of increased scrutiny,
implying that primary prevention in the Yorkshire area of the UK has failed to control trends in incidence. Mortality, in contrast,
appears to be levelling off, indicating that secondary prevention has been more effective.
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Although time trends in the incidence of and mortality from
malignant melanoma (MM) in the UK have been reported by many
studies, relatively few studies have looked at these changes in relation
to the stage of disease (Melia et al, 1995; Mackie et al, 1997, 2002;
Holme et al, 2001). Since the 1990s, the Northern and Yorkshire
Cancer Registry and Information Service (NYCRIS) have collected
information on Breslow thickness, the most commonly used measure
of stage. This has provided us with a unique opportunity to
investigate recent trends in the incidence of MM in relation to stage
using population-based registry data. Because death certificates do
not contain any information on stage of disease, it is not possible to
look at equivalent mortality data. By analysing the pattern of survival
in the incident cases, it is possible, however, to investigate the effect of
changes in the pattern of melanoma incidence on disease outcome.
DATA AND METHODS
Cases of primary invasive and in situ MM (ICD10 (World Health
Organization, 1992) codes C43 and D03) diagnosed between 1st
January 1993 and 31st December 2003 in the former Yorkshire
Health Authority were identified from the NYCRIS database.
Relevant patient and tumour characteristics (such as age, sex,
Breslow thickness, histological type and body site) were extracted.
Breslow thickness was divided into three groups representing thin
(o1.5mm), intermediate (1.5–4.0mm) and thick (44.0mm)
tumours, according to the groupings specified on the histopatho-
logy forms. As a measure of socioeconomic status, the income
domain score of Index of Multiple Deprivation 2000 (Department
of the Environment, Transport and the Regions, 2000) was
matched with the patient postcode and divided into quintiles.
Incidence rates were calculated as 3-year rolling averages using
the 1998 Yorkshire population as a denominator and standardised
to the European population. Melanoma mortality rates were
obtained from the Cancer Information System (CIS) maintained by
NYCRIS (Northern & Yorkshire Cancer Registry & Information
Service, 2005). Information on mortality was not available for in
situ melanoma, therefore the rates presented refer to invasive MM
only.
Survival analyses were performed with the survival period
defined as the time difference between the date of diagnosis and
5-year follow-up, the date of death or the date of censoring (31st
May 2005). In situ tumours were excluded from these analyses, as
survival rates are very high (B100%) (American Joint Committee
on Cancer, 2002). Five-year relative survival estimates (Ederer
et al, 1961) were calculated and multivariable analyses were
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yperformed using the Cox proportional hazards regression model
(Cox, 1972). All analyses were performed using STATA 9.0
(StataCorp, TX, USA).
RESULTS
Incidence
Between 1993 and 2003, 5513 patients were diagnosed with MM in
the Yorkshire area. Of these, 4178 were diagnosed with invasive
disease and 1335 with in situ MM. Breslow thickness was recorded
in 90.8% of cases overall, increasing from 70.9% in 1993 to 96.2%
in 2003.
Over the study period, the age standardised incidence of
invasive MM in male subjects steadily increased from 5.4 per
100000 in 1993–1995 to 9.7 per 100000 in 2001–2003 (Figure 1).
In female subjects, the rate increased from 7.5 per 100000 in
1993–1995 to 13.1 per 100000 in 2001–2003, with most of the
increase occurring after the period 1998–2000. There were slight
increases in the incidence of in situ tumours over this time period,
rising from 2.0 to 2.5 per 100000 in male subjects and from 3.2 to
3.4 per 100000 in female subjects.
Looking at the rates by Breslow thickness, the general patterns
for invasive MM were mirrored for thin tumours, with increases in
all age groups, from 2.6 to 6.1 per 100000 in male subjects and 5.3
to 9.5 per 100000 in female subjects during the study period
(Figure 1). Proportionally, 77.1% of invasive tumours in the 15- to
44-year age group were classified as thin, compared to 67.8 and
45.2% in those aged 45–64 years and over 65 years. The incidence
of intermediate and thick tumours increased slightly in both male
and female subjects, with most of the increase in intermediate
tumours and all of the increase in thick tumours seen in those aged
over 65 years (Figure 2).
Superficial spreading melanoma was the most common
histological type recorded, followed by nodular melanoma. During
the study period, the proportion of cases recorded as superficial
spreading melanoma rose from 53 to 64%. The increase in
superficial spreading melanoma was driven by an increase in thin
tumours, with a slight increase in the incidence of intermediate
tumours (Figure 3). For nodular melanoma, the picture was quite
different, with the rate of thin tumours being less than that of
intermediate and thick tumours. The numbers of acral lentiginous
and lentigo maligna melanomas were too small to observe any
clear patterns.
Analysis by body site revealed that in male subjects the increases
in thin tumours were mainly seen for the trunk. In female subjects,
the rates remained much higher for tumours of the lower limb.
However, increases were seen in female subjects for all body sites,
with a doubling of the rate of thin tumours of the head and neck,
trunk and upper limbs (data not shown).
Mortality
There was a steady decrease in the female age standardised
mortality rate after the period 1995–1997, from 2.7 per 100000 to
2.2 per 100000 in 2000–2002 (Figure 4). The pattern in male
subjects was less clear. In 1993–1995, the rate was 2.9 per 100000
and this remained steady until 1996–1998, after which it increased
to a peak of 3.3 per 100000 in 1998–2000 and then decreased to 2.9
per 100000 in 2000–2002. Mortality appears to have stabilised or
decreased in recent years across all age groups, except for a slight
increase in the rate for women aged 45–64 years.
Survival
Overall 5-year relative survival was 76.8% (95% CI 75.3–78.2). This
varied from 70.0% (95% CI 67.4–72.3) for male subjects to 81.5%
(95% CI 79.7–83.2) for female subjects. In relation to Breslow
thickness, survival was 91.8% (95% CI 90.4–93.1) for patients with
thin tumours, 63.5% (95% CI 60.0–66.7) for those with
intermediate tumours and 41.5% (95% CI 36.7–46.3) for those
with thick tumours.
In multivariable analyses, Breslow thickness was the most
important prognostic factor, with a hazard ratio (HR) of 6.06 (95%
CI 4.64–7.93) for patients with thick tumours compared to those
with thin tumours, after adjustment for age, sex, histological type
body site and deprivation quintile (Table 1). Female survival was
significantly better than that in male subjects after adjustment
(HR¼0.67; 95% CI 0.56–0.80) and older age was associated with
an increased risk of death (HR¼1.04; 95% CI 1.04–1.05 per
annum). Patients living in the two most deprived quintiles had a
worse prognosis (HR¼1.40; 95% CI 1.05–1.88 for quintile 5
compared with quintile 1). There was no change in survival in
relation to individual year of diagnosis (HR¼1.00; 95% CI 0.97–
1.03).
DISCUSSION
In this population-based cancer registry study, we have shown
that, over the 10-year period to 2003, the incidence of invasive MM
has increased in both male and female subjects in the Yorkshire
region of England. In female subjects, the increase has been
Males
0
2
4
6
8
10
12
14
1994 1995 1996 1997 1998 1999 2000 2001 2002
Year of diagnosis (3-year rolling average − middle year is given)
1994 1995 1996 1997 1998 1999 2000 2001 2002
Year of diagnosis (3-year rolling average − middle year is given)
R
a
t
e
 
p
e
r
 
1
0
0
 
0
0
0
0
2
4
6
8
10
12
14
R
a
t
e
 
p
e
r
 
1
0
0
 
0
0
0
<1.5 mm 1.5−4.0 mm >4.0 mm All invasive In situ <1.5 mm 1.5−4.0 mm >4.0 mm All invasive In situ
Females
Figure 1 Age standardised incidence rates of MM by Breslow thickness: male and female subjects, Yorkshire UK, 1993–1995 to 2001–2003.
Cutaneous MM in the Yorkshire region of England
A Downing et al
92
British Journal of Cancer (2006) 95(1), 91–95 & 2006 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yparticularly pronounced since 1998 and comes after a period of
relative stability. These results suggest a failure to stem the rise in
incidence of this form of cancer, despite efforts to the contrary.
These trends compare well with those from other studies.
Several authors reported a levelling off in incidence rates in the
1990s in the UK (Mackie et al, 1997, 2002; Newnham and Moller,
2002) and other white Caucasian populations (Hall et al, 1999;
Marrett et al, 2001; de Vries et al, 2003). Recent MM incidence
rates for the UK, covering the period 1993–2002, show similar
trends, with relatively stable incidence rates between 1993 and
1999 but a sharp rise in incidence thereafter (Cancer Research UK,
2005). There is, therefore, a high degree of conformity in the
incidence trends between Yorkshire and the UK overall.
For both sexes, the increases have been predominantly of thin,
early-stage tumours, as has been the trend in other populations
(Hall et al, 1999; Marrett et al, 2001; de Vries et al, 2004). Increases
in thick tumours were seen mainly in the older age groups and
similar trends have been observed elsewhere (Murray et al, 2005).
The observed increase in thin tumours may suggest a trend
towards earlier diagnosis due to increased awareness, but public
health campaigns directed towards early detection have been in
existence since 1987 (Melia et al, 1995) and so this does not fully
explain the increase in female subjects seen after 1999. During the
1980s and the 1990s, as a part of these public health campaigns, a
number of pigmented lesion clinics were opened. These may have
added to the increase in the diagnosis of thin tumours, while as yet
having little effect on thicker tumours. In the Yorkshire region, we
are aware of a number of such clinics but when the data are broken
down by Cancer Network (data not shown), the observed variation
does not correspond with the location of these clinics. It seems
unlikely, therefore, that the opening of these clinics explains the
overall increased incidence.
The proportion of tumours classified as superficial spreading
melanomas (predominantly thin tumours) increased in the time
period studied as has been reported previously in Scotland
(MacKie et al, 2002). An increasing incidence of MM, particularly
of thinner tumours, has led some authors to suggest that these
trends are at least in part artefactual. Welch et al (2005) have
suggested that increases in MM seen in the US could represent an
‘overdiagnosis’ owing to increased scrutiny and an increased
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Figure 2 Age standardised incidence rates of MM by Breslow thickness:
15–44 years, 45–64 years, over 65 years, Yorkshire UK, 1993–1995 to
2001–2003.
Table 1 Unadjusted and adjusted Cox proportional hazards regression
analysis of 5-year survival of patients with cutaneous malignant melanoma
Variable N
Unadjusted HR
(95% CI)
Adjusted HR
a
(95% CI)
Age
Change per year 3127 1.05 (1.05–1.06) 1.04 (1.04–1.05)
Sex
Male 1238 1.00 1.00
Female 1899 0.57 (0.48–0.67) 0.67 (0.56–0.80)
Breslow
b
o1.5mm 2012 1.00 1.00
1.5–4.0mm 757 5.58 (4.49–6.92) 3.62 (2.85–4.60)
44.0mm 358 12.23 (9.78–15.31) 6.06 (4.64–7.93)
Site
b
Head and neck 553 1.00 1.00
Lower limb 1104 0.48 (0.38–0.60) 0.90 (0.70–1.17)
Trunk 832 0.65 (0.52–0.82) 1.16 (0.91–1.50)
Upper limb 638 0.50 (0.39–0.65) 0.91 (0.70–1.20)
Histology
b
Acral lentiginous 63 1.00 1.00
Lentigo maligna 183 0.64 (0.36–1.14) 0.82 (0.44–1.52)
Nodular 753 1.52 (0.94–2.44) 1.28 (0.78–2.09)
Superficial spreading 2128 0.36 (0.22–0.57) 1.02 (0.62–1.68)
IMD quintile
1 (affluent) 1014 1.00 1.00
2 892 1.01 (0.80–1.27) 1.06 (0.84–1.33)
3 475 1.18 (0.91–1.53) 1.08 (0.83–1.41)
4 455 1.65 (1.30–2.11) 1.53 (1.20–1.96)
5 (deprived) 274 1.63 (1.22–2.17) 1.40 (1.05–1.88)
Year
Change per year 3127 1.00 (0.97–1.03) 1.00 (0.97–1.03)
HR¼hazard ratio; IMD¼Index of Multiple Deprivation.
aEach variable is adjusted for
all other covariates in the table.
bWhere information was missing or recorded as
‘unspecified’, the records have been excluded from the analysis.
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ynumber of biopsies being taken. They reported a correlation
between MM rates and biopsy rates in those aged over 65 years,
whereas mortality rates remained stable. In response, de Vries and
Coebergh (2005) note that in many European countries mortality
from MM has continued to increase, especially in older
men, suggesting that part of the observed increases are real.
Furthermore, despite the increases seen in thin tumours in
our data, the incidence of in situ tumours has remained
relatively constant. If the reported increase in the incidence of
thin tumours was a function of increased biopsy rates, then we
would have expected a similar, or even larger, increase in in situ
lesions. Finally, whereas a large proportion of the increase in
incidence has been seen in thin tumours, the incidence of
intermediate and thick tumours has increased slightly, whereas
we would expect these to begin to decrease if it was simply earlier
detection (lead-time bias).
This increase in thin tumours may, however, represent a change
in the type of melanoma being removed, which may in turn result
from an increase in intermittent sun exposure. Superficial
spreading melanoma may have a stronger relationship to this
form of exposure than other melanomas (de Vries and Coebergh,
2004) and evidence certainly suggests that the popularity of sunny
holidays with high levels of sun exposure continues to increase in
the UK population (National Statistics, 2005).
Despite the adverse association between tumour thickness and
risk of death (Holme et al, 2001; MacKie et al, 2002) and the
increased incidence of thicker tumours in older people, mortality
rates in those aged over 65 years do not appear to have increased
in the past few years in Yorkshire. Although this study suggests a
failure of primary prevention, the levelling off of mortality despite
the increased incidence supports the view that secondary
prevention (early detection) has been more effective. Some authors
have challenged this view (Burton and Armstrong, 1994; Swerlick
and Chen, 1996) and have suggested that increased surveillance
has led to the removal of superficial spreading melanoma with
reduced malignant potential. This possibility will be explored as
greater understanding of the biological behaviour of tumours with
differing patterns of somatic mutations becomes clearer (Curtin
et al, 2005).
Breslow thickness remains the most important prognostic factor
in survival from MM, as shown in our multivariable analysis. Male
subjects have worse survival outcomes than female subjects, even
after adjusting for the effects of age, Breslow thickness, histology
and body site, although this sex effect is not yet understood.
*Data were not available for the year 2003
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Figure 4 Age standardised mortality rates of invasive cutaneous malignant melanoma by sex, Yorkshire UK, 1993–1995 to 2001–2003. *Data were not
available for the year 2003.
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remains after adjustment for other known determinants of
survival. This observation has been reported before in studies
from North America (Berwick, 1999) and Scotland (Mackie and
Hole, 1996). There are no treatments known to affect survival from
MM and this, therefore, has important implications for our
understanding of human responses to cancer. The presence of
ulceration is also known to affect prognosis and this has now
been incorporated into the American Joint Committee on Cancer
staging system (American Joint Committee on Cancer, 2002). In
this study, however, we were unable to include information on
ulceration, as this was only available in 27% of cases.
In conclusion, the incidence of MM continues to rise in the
Yorkshire region: indeed a marked increase in female subjects has
occurred in the period since 1999. This study therefore supports
the view that primary prevention in this part of the UK has been
inadequate to control the increased incidence seen in the UK since
the beginning of the 20th century. Mortality appears to be levelling
off, which supports the view that secondary prevention has been
more effective. UK populations are travelling increasingly to sunny
destinations, leading to increased intermittent sun exposure.
This seems likely to have the effect of increasing incidence further
in future years, albeit predominantly of good prognosis thin
tumours.
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